{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T17:39:34Z","timestamp":1792172374434,"version":"4.4.0"},"reference-count":26,"publisher":"American Society for Microbiology","issue":"5","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"HHS | National Institutes of Health","doi-asserted-by":"publisher","award":["UM1AI104681"],"award-info":[{"award-number":["UM1AI104681"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"HHS | National Institutes of Health","doi-asserted-by":"publisher","award":["R21AI288338"],"award-info":[{"award-number":["R21AI288338"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"HHS | National Institutes of Health","doi-asserted-by":"publisher","award":["R21AI111037"],"award-info":[{"award-number":["R21AI111037"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"HHS | National Institutes of Health","doi-asserted-by":"publisher","award":["K08AI114883"],"award-info":[{"award-number":["K08AI114883"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2017,5]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>We identified four<jats:italic>bla<\/jats:italic><jats:sub>KPC-3<\/jats:sub>mutations in ceftazidime-avibactam-resistant clinical<jats:named-content content-type=\"genus-species\">Klebsiella pneumoniae<\/jats:named-content>isolates, corresponding to D179Y, T243M, D179Y\/T243M, and EL165-166 KPC-3 variants. Using site-directed mutagenesis and transforming vectors into<jats:named-content content-type=\"genus-species\">Escherichia coli<\/jats:named-content>, we conclusively demonstrated that mutant<jats:italic>bla<\/jats:italic><jats:sub>KPC-3<\/jats:sub>encoded enzymes that functioned as extended-spectrum \u03b2-lactamases; mutations directly conferred higher MICs of ceftazidime-avibactam and decreased the MICs of carbapenems and other \u03b2-lactams. Impact was strongest for the D179Y mutant, highlighting the importance of the KPC \u03a9-loop.<\/jats:p>","DOI":"10.1128\/aac.02534-16","type":"journal-article","created":{"date-parts":[[2017,2,22]],"date-time":"2017-02-22T01:30:22Z","timestamp":1487727022000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":183,"title":["Mutations in<i>bla<\/i><sub>KPC-3<\/sub>That Confer Ceftazidime-Avibactam Resistance Encode Novel KPC-3 Variants That Function as Extended-Spectrum \u03b2-Lactamases"],"prefix":"10.1128","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0634-8211","authenticated-orcid":false,"given":"Ghady","family":"Haidar","sequence":"first","affiliation":[{"name":"University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelius J.","family":"Clancy","sequence":"additional","affiliation":[{"name":"University of Pittsburgh, Pittsburgh, Pennsylvania, USA"},{"name":"XDR Pathogen Laboratory, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA"},{"name":"VA Pittsburgh Healthcare System, Pittsburgh, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan K.","family":"Shields","sequence":"additional","affiliation":[{"name":"University of Pittsburgh, Pittsburgh, Pennsylvania, USA"},{"name":"XDR Pathogen Laboratory, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binghua","family":"Hao","sequence":"additional","affiliation":[{"name":"XDR Pathogen Laboratory, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoji","family":"Cheng","sequence":"additional","affiliation":[{"name":"University of Pittsburgh, Pittsburgh, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Hong","family":"Nguyen","sequence":"additional","affiliation":[{"name":"University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA"},{"name":"University of Pittsburgh, Pittsburgh, Pennsylvania, USA"},{"name":"XDR Pathogen Laboratory, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00869-16"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2014.06.010"},{"key":"e_1_3_3_4_2","volume-title":"FAQs about choosing and implementing a CRE definition","author":"Centers for Disease Control and Prevention","unstructured":"Centers for Disease Control and Prevention. FAQs about choosing and implementing a CRE definition. Centers for Disease Control and Prevention, Atlanta, GA. https:\/\/www.cdc.gov\/hai\/organisms\/cre\/definition.html ."},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.06268-11"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/1469-0691.12697"},{"key":"e_1_3_3_7_2","volume-title":"Avycaz (ceftazidime-avibactam) prescribing information","author":"Forest Pharmaceuticals, Inc","year":"2016","unstructured":"Forest Pharmaceuticals, Inc. 2016. Avycaz (ceftazidime-avibactam) prescribing information. Forest Pharmaceuticals, Inc., Cincinnati, OH."},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw636"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02097-16"},{"key":"e_1_3_3_10_2","volume-title":"CLSI M100-S25","author":"Clinical and Laboratory Standards Institute","year":"2015","unstructured":"Clinical and Laboratory Standards Institute. 2015. Performance standards for antimicrobial susceptibility testing; 25th informational supplement. CLSI M100-S25. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00678-15"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkv094"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M112.348540"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00734-08"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.18.4.657-686.2005"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01009-09"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkn444"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200363040-00002"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2007.01857.x"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkl381"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(14)70950-8"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00135-13"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkp197"},{"key":"e_1_3_3_24_2","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1093\/cid\/civ007","article-title":"Editorial commentary: bloodstream infection caused by extended-spectrum beta-lactamase-producing Gram-negative bacteria: how to define the best treatment regimen?","volume":"60","author":"Perez F","year":"2015","unstructured":"Perez F BonomoRA. 2015. Editorial commentary: bloodstream infection caused by extended-spectrum beta-lactamase-producing Gram-negative bacteria: how to define the best treatment regimen?Clin Infect Dis60:1326\u20131329.","journal-title":"Clin Infect Dis"},{"key":"e_1_3_3_25_2","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1093\/cid\/civ003","article-title":"Carbapenem therapy is associated with improved survival compared with piperacillin-tazobactam for patients with extended-spectrum beta-lactamase bacteremia","volume":"60","author":"Tamma PD","year":"2015","unstructured":"Tamma PD HanJH RockC HarrisAD LautenbachE HsuAJ AvdicE CosgroveSE, Antibacterial Resistance Leadership Group. 2015. Carbapenem therapy is associated with improved survival compared with piperacillin-tazobactam for patients with extended-spectrum beta-lactamase bacteremia. Clin Infect Dis60:1319\u20131325.","journal-title":"Clin Infect Dis"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir790"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir793"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02534-16","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02534-16","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,15]],"date-time":"2025-06-15T15:26:31Z","timestamp":1750001191000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.02534-16"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["10.1128\/AAC.02534-16"],"URL":"https:\/\/doi.org\/10.1128\/aac.02534-16","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"2016-11-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-02-07","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-04-24","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e02534-16"}}